Method for making humanized antibodies

full-text

print

pdf

permalink

Inventors

Carter, Paul J.
Presta, Leonard G.

Application #

705392

Filed

Nov-2-2000

Published

Apr-13-2004

Current US Class

424/130.1
424/133.1
424/136.1
424/141.1
424/155.1
435/7.1
530/387.1
530/388.1
530/388.8
530/388.85

International Classes

A61K 039/395

Field of Search

435/7.1 424/130.1 424/133.1 424/136.1 424/155.1 424/141.1 530/387.1 530/388.1 530/388.8 530/388.85

Assignee

Genentech, Inc. (South San Francisco, CA)

Examiners

Ungar; Susan

Attorney, Agent or Firm

Lee; Wendy M.

US Patent References

Referenced by:

View Backward References

Other References

1/ Roitt, I et al (eds). Immunol. 14.sup.th ed. Mosby, London, p. 9.6, 1998.* 2/ Kimmel J. Neurosurg 66 : 161-171, 1987.* 3/ Freshney. Culture of Animal cells, A manual of Basicc Tech., Alan Liss Inc, N.Y. p. 4., 1983.* 4/ Dermer, Bio/Technology 12: 320, 1994.* 5/ Sherman, LA, Crit. Rev. Immunol. 18(1-2) : 47-54, 1998.* 6/ Grupa. Science 278 : 1041-1042, 1997.* 7/ Jain. Sci. Am. 271 : 58-65, 1994.* 8/ Curti, Crit. Rev. Oncol/Hematol. 14 : 29-39, 1993.* 9/ Hartwell, Science, 278 : 1064-1068, 1997.* 10/ Boon . Adv. Cancer Res. 58 : 177-210, 1992.* Debrin, JA, 1986, Proceed Natl Acad Sci, USA, 83 (23): 9129-33.* Primus FJ et al, 1990, Cancer Immunology, Immunotherapy:CII (Germany, WEST) 31(6): 349-57.* Riechmann, L, 1988, Nature, 332: 323-327.* Zu Putlitz, J, 1990, Bio/technology, 8(7): 651-4.* William E. Paul, M.D. ed., 3d ed. 1993, FUNDAMENTAL, p. 242.* Rhodes, P., "Recombinant antibodies from CHO cells" Abstr Pap Am Chem Soc (Abstract No. 60 from the 199th American Chemical Society National Meeting held in Boston, MA Apr. 22-27, 1990) 199 (1-2) :BIOT 60 (Apr. 1990). U.S. patent application Ser. No. 07/934,373, Carter et al., filed Aug. 21, 1992. U.S. patent application Ser. No. 08/437,642, Carter et al., filed May 9, 1995. U.S. patent application Ser. No. 09/115,800, Carter et al., filed Jul. 15, 1998. Adair et al., "Humanization of the murine anti-human CD3 monoclonal antibody OKT3" Hum. Antibod. Hybridomas 5:41-47 (1994). Amit et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution" Science 233:747-753 (Aug. 1986). Amzel and Poljak, "Three-dimensional structure of immunoglobulins" Ann. Rev. Biochem. 48:961-967 (1979). Amzel et al., "The Three Dimensional Structure of a Combining Region-Ligand Complex of Immunoglobulin NEW at 3.5-A Resolution" Proc. Natl. Acad. Sci. USA 71(4) :1427-1430 (Apr. 1974). Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185.sup.HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" J. Clin. Oncol. 14 (3) : 737-744 (Mar. 1996). Beverley & Callard, "Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody" European Journal of Immunology 11:329-334 (1981). Bindon et al., "Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as Clq" Journal of Experimental Medicine 168(1):127-142 (Jul. 1988). Bird et al., "Single-chain antigen-binding proteins" Science 242:423-426 (Oct. 1988). Boulianne et al., "Production of functional chimaeric mouse/human antibody" Nature 312:643-646 (Dec. 13, 1984). Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G.sub.1 fragments" Science 229:81-83 (Jul. 1985). Brown et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" Proc. Natl. Acad. Sci. USA 88:2663-2667 (Apr. 1991). Brown, Jr. et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" Proc. Natl. Acad. Sci. USA 88:2663-2667 (1991). Bruccoleri et al., "Structure of antibody hypervariable loops reproduced by a conformational search algorithm" Nature 335:564-568 (Oct. 1988). Bruccoleri, "Structure of antibody hypervariable loops reproduced by a conformational search algorithm" Nature 336:266 (1988). Bruggemann, M. et al., "Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies" Journal of Experimental Medicine 166:1351-1361 (1987). Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" Journal of Cell Biology 111:2129-2138 (1990). Caron et al., "Biological and Immunological Features of Humanized M195 (Anti-CD33) Monoclonal Antibodies" Cancer Research 52:6761-6767 (Dec. 1992). Carter et al., "High level Escherichia coli expression and production of a bivalent humanized antibody fragment" Bio/Technology 10:163-167 (1992). Carter et al., "Humanization of an anti-p185.sup.HER2 antibody for human cancer therapy" Proc. Natl. Acad. Sci. 89:4285-4289 (May 1992). Casale et al., "Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis" J. Allergy Clin. Immunol. 100:110-121 (1997). Cheetham, J., "Reshaping the antibody combining site by CDR replacement-tailoting or tinkering to fit?" Protein Engineering 2(3):170-172 (1988). Chothia & Lesk, "The relation between the divergence of sequence and structure in proteins" EMBO Journal 5(4):823-826 (1986). Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" J. Mol. Biol. 196(4):901-917 (1987). Chothia et al., "Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains" Journal of Molecular Biology 186:651-663 (1985). Chothia et al., "Principles of protein-protein recognition" Nature 256:705-708 (1975). Chothia et al., "The predicted structure of immunoglobulin D1.3 and its comparison with the crystal structure" Science 233:755-758 (Aug. 15, 1986). Chothia et al., "Transmission of conformational change in insulin" Nature 302:500-505 (1983). Chothia, C. et al., "Conformations of immunoglobulin hypervariable regions" Nature 342(6252):877-883 (1989). Clark et al., "The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies" European Journal of Immunology 19:381-388 (1989). Co & Queen, "Humanized antibodies for therapy" Nature 351:501-502 (Jun. 1991). Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen" J. of Immunology 148(4):1149-1154 (Feb. 1992). Co et al., "Humanized Anti-Lewis Y Antibodies: In Vitro Properties and Pharmacokinetics in Rhesus Monkeys" Cancer Research 56:1118-1125 (Mar. 1996). Co et al., "Humanized antibodies for antiviral therapy" Proc. Natl. Acad. Sci. USA 88:2869-2873 (Apr. 1991). Colman et al., "Crystal and Molecular Structure of the Dimer of Variable Domains of the Bence-Jones Protein ROY" J. Mol. Biol. 116:73-79 (1977). Colman et al., "Three-dimensional structure of a complex of antibody with influenza virus neuraminidase" Nature 326:358-363 (Mar. 1987). Cook et al., "A map of the human immunoglobulin V.sub.H locus completed by analysis of the telometric region of chromosome 14q" Nature Genetics 7:162-168 (Jun. 1994). Corti et al., "Idiotope Determining Regions of a Mouse Monoclonal Antibody and Its Humanized Versions" J. Mol. Biol. 235:53-60 (1994). Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene" Science 230:1132-1139 (1985). Couto et al., "Anti-BA46 Monoclonal Antibody Mc3 Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization" Cancer Research Supplement 55:1717-1722 (1995). Couto et al., "Humanization of KC4G3, and Anti-Human Carcinoma Antibody" Hybridoma 13:215-219 (1994). Darsley & Rees, "Nucleotide sequences of five anti-lysozyme monoclonal antibodies" EMBO Journal 4(2):393-398 (1985). Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins" Nucleic Acids Research 19(9):2471-2476 (May 11, 1991). Davies & Metzger, "Structural Basis of Antibody Function" Ann. Rev. Immunol. 1:87-117 (1983). Davies et al., "Antibody-Antigen Complexes" Journal of Biological Chemistry 263(22):10541-10544 (Aug. 1988). Davies et al., "Antibody-Antigen Complexes" Ann. Rev. Biochem. 59:439-473 (1990). Eigenbrot et al., "X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of V.sub.H Residues 59 to 65" Proteins: Structure, Function, and Genetics 18:49-62 (1994). Eigenbrot et al., "X-ray structures of the antigen-binding domains from three variants of humanized anti-p185.sup.HER2 antibody 4D5 and comparison with molecular modeling" J. Mol. Biol. 229:969-995 (1993). Ellis et al., "Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma" The Journal of Immunology pps. 925-937 (1995). Ellison et al., "The nucleotide sequence of a human immunoglobulin C.sub..gamma.1 gene" Nucleic Acids Research 10(13):4071-4079 (1982). Emery & Adair, "Humanised monoclonal antibodies for therapeutic applications" Exp. Opin. Invest. Drugs 3(3):241-251 (1994). Epp et al., "Crystal and Molecular Structure of a Dimer Composed of the Variable Portions of the Bence-Jones Protein REI" European Journal of Biochemistry 45:513-524 (1974). Epp et al., "The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution" Biochemistry 14(22):4943-4952 (1975). Fahy et al., "The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects" Am J. Respir. Crit. Care Med 155:1828-1834 (1997). Fanger et al., "Bispecific antibodies and targeted cellular cytotoxicity" Immunology Today 12(2):51-54 (1991). Fanger et al., "Cytotoxicity mediated by human Fc receptors for IgG" Immunology Today 10(3):92-99 (1989). Feldmann et al., "A Hypothetical Space-Filling Model of the V-Regions of the Galactan-Binding Myeloma Immunoglobulin J539" Molecular Immunology 18(8):683-698 (1981). Fendley et al., "The Extracellular Domain of HER2/neu Is a Potential Immunogen for Active Specific Immunotherapy of Breast Cancer" J. Biol. Resp. Mod. 9:449-455 (1990). Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" Cancer Research 50:1550-1558 (Mar. 1, 1990). Foote et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops" J. Mol. Biol. 224:487-499 (1992). Foote, J., "Humanized Antibodies" Nova acta Leopoldina 61(269):103-110 (1989). Furey et al., "Structure of a novel Bence-Jones protein (Rhe) fragment at 1.6 A resolution" J. Mol. Biol. 167(3):661-692 (Jul. 5, 1983). Glennie et al., "Preparation and Performance of Bispecific F(ab'.gamma.).sub.2 Antibody Containing Thioether-Linked Fab'.gamma. Fragments" J. Immunol. 139(7):2367-2375 (Oct. 1, 1987). Gonzalez et al., "Humanization of Murine 6G425:An Anti-IL8 Monoclonal Antibody Which Blocks Binding of IL8 to Human Neutrophils" 1996 Keystone Symposia on Exploring and Exploiting Antibody and Ig Superfamily Combining Sites (Poster) pps. 1-21 (Feb. 1996). Gorman et al., "Reshaping a therapeutic CD4 antibody" Proc. Natl. Acad. Sci. USA 88(10):4181-4185 (May 15, 1991). Gregory et al., "The solution conformations of the subclasses of human IgG deduced from sedimentation and small angle X-ray scattering studies" Molecular Immunology 24(8):821-829 (Aug. 1987). Gussow & Seemann, "Humanization of Monoclonal Antibodies" Meth. Enzymology, Academic Press, Inc. vol. 203:99-121 (1991). Hale, G. et al., "Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H" Lancet 2(8625):1394-1399 (Dec. 17, 1988). Harris et al., "Therapeutic Antibodies--The Coming of Age" TIBTECH 11:42-44 (Feb. 1993). Hieter et al., "Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments" Cell 22(Part 1):197-207 (1980). Hieter et al., "Evolution of Human Immunoglobulin K J Region Genes" The Journal of Biological Chemistry 257:1516-1522 (1982). Houghton, A., "Building a better monoclonal antibody" Immunology Today 9(9):265-267 (1988). Huber et al., "Crystallographic structure studies of an IgG molecule and an Fc fragment" Nature 264:415-420 (Dec. 2, 1976). Hudziak et al., "p185.sup.HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" Molecular & Cellular Biology 9(3):1165-1172 (Mar. 1989). Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli" Proc. Natl. Acad. Sci. USA 85:5879-5883 (Aug. 1988). Isaacs et al., "Humanised Monoclonal Antibody Therapy for Rheumatoid Arthritis" Lancet 340:748-752 (Sep. 26, 1992). Jaffers et al., "Monoclonal Antibody Therapy, Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression" Transplantation 41(5):572-578 (May 1986). Johnson et al., "Biological and Molecular Modeling Studies Comparing Murine Monoclonal Antibodies with Their Engineered Chimeric and Humanized Counterparts" J. Cell. Biochem. Suppl 0 (13 Part A) (18th Ann. UCLA Symp on Mol. & Cell. Biol., Park City, UT Jan. 17-22, 1989) pps. 87 (1989). Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" Nature 321:522-525 (May 29, 1986). Junghans et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders" Cancer Research 50(5):1495-1502 (Mar. 1, 1990). Kabat E., "Origins of Antibody Complementarity and Specificity--Hypervariable Regions and the Minigenen Hypothesis" J. of Immunology 125(3):961-969 (Sep. 1980). Kabat et al. Sequences of Proteins of Immunological Interest, Bethesda, MD:National Institutes of Health pps. iii-xxiii, 41-76 and 160-167 (1987). Kabat et al. Sequences of Proteins of Immunological Interest, U.S. Dept. of Health and Human Services, NIH, 5th edition vol. 1:103-108, 324-331 (1991). Kabat et al., "Sequences of Proteins of Immunological Interest", Bethesda, MD:National Institute of Health pps. 14-32 (1983). Kabat et al., "Sequences of Proteins of Immunological Interest, 4th Edition" pps. iii-xxvii, 41-76, 160-175 (1987). Kettleborough et al., "Humanization of a Mouse Monoclonal Antibody by CDR-grafting: the Importance of Framework Residues on Loop Conformation" Protein Engineering 4(7):773-783 (1991). Kindt & Capra The Antibody Enigma, New York:Plenum Press pps. 79-86 (1984). King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" Science 229:974-976 (Sep. 1985). Lazar et al., "Transforming Growth Factor .alpha.: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" Molecular & Cellular Biology 8(3):1247-1252 (Mar. 1988). Lesk & Chothia, "Evolution of Proteins Formed by .beta.-Sheets" J. Mol. Biol. 160:325-342 (1982). Lesk & Chothia, "The response of protein structures to amino-acid sequence changes" Phil. Trans. R. Soc. Lond. A 317:345-356 (1986). Lesk, Arthur M., "How Different Amino Acid Sequences Determine Similar Protein Structures: The Structure and Evolutionary Dynamics of the Globins" J. Mol. Biol. 136:225-270 (1980). Love et al, "Recombinant antibodies possessing novel effector functions" Methods in Enzymology 178:515-527 (1989). Lupu et al., "Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185.sup.erbB2" Science 249:1552-1555 (1990). Maeda et al., "Construction of Reshaped Human Antibodies with HIV-neutralizing Activity" Hum. Antibod. Hybridomas 2:124-134 (Jul. 1991). Margni RA and Binaghi RA, "Nonprecipitating asymmetric antibodies" Ann. Rev. Immunol. 6:535-554 (1988). Margolies et al., "Diversity of light chain variable region sequences among rabbit antibodies elicited by the same antigens." Proc. Natl. Acad. Sci. USA 72:2180-84 (Jun. 1975). Mariuzza et al., "The Structure Basis of Antigen-Antibody Recognition" Ann. Rev. Biophys. Biophys. Chem. 16:139-159 (1987). Marquart et al., "Crystallographic refinement and atomic models of the intact immunoglobulin molecule Kol and its antigen-binding fragment at 3.0 A and 1.0 A resolution" J. Mol. Biol. 141(4):369-391 (Aug. 25, 1980). Mathieson et al., "Monoclonal-Antibody Therapy in Systemic Vasculitis" New England J. of Medicine pps. 250-254 (Jul. 1990). Matsumura et al., "Hydrophobic stabilization in T4 lysozyme determined directly by multiple substitutions of Ile 3" Nature 334:406-410 (1988). Mian, IS et al., "Structure, function and properties of antibody binding sites" J. Mol. Biol. 217(1):133-151 (Jan. 5, 1991). Miller, R. et al., "Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma" Blood 62:988-995 (1983). Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" Proc. Natl. Acad. Sci. USA 81:6851-6855 (Nov. 1984). Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" Science 229:1202-1207 (Sep. 20, 1985). Nadler et al., "Immunogenicity of Humanized and Human Monoclonal Antibodies" Clin. Pharmacology & Therapeutics pps. 180 (Feb. 1994). Nakatani et al., "Humanization of mouse anti-human IL-2 receptor antibody B-B10" Protein Engineering 7:435-443 (1994). Nelson, H., "Targeted Cellular Immunotherapy with Bifunctional Antibodies" Cancer Cells 3:163-172 (1991). Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function" Nature 314:268-270 (Mar. 21, 1985). Neuberger et al., "Antibody Engineering" Proceedings 8th Intl. Biotech. Symp., Paris II:792-799 (1988). Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" Nature 312:604-608 (Dec. 13, 1984). Newmark, P., "Making Chimeric Antibodies Even More Human" Bio/Technology 6:468 (May 1988). Nishimura et al., "Human c-erbB-2 Proto-Oncogene Product as a Target for Bispecific-Antibody-Directed Adoptive Tumor Immunotherapy" Int. J. Cancer 50:800-804 (1992). Nitta et al., "Preliminary trial of specific targeting therapy against malignant glioma" Lancet 335(8686):368-371 (Feb. 17, 1990). Nitta, T. et al., "Bispecific F(ab').sub.2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells" European Journal of Immunology 19:1437-1441 (1989). Nolan et al., "Bifunctional antibodies: concept, production and applications" Biochimica et Biophysica Acta 1040:1-11 (1990). Novotny et al., "Structural invariants of antigen binding: comparison of immunoglobulin V.sub.L -V.sub.H and V.sub.L -V.sub.L domain dimers" Proc. Natl. Acad. Sci. USA 82(14):4592-4596 (Jul. 1985). O'Connor et al., "Calcium Dependence of an Anti-Protein C Humanized Antibody Involves Framework Residues" (manuscript). Ohtomo et al., "Humanization of Mouse ONS-M21 Antibody with the Aid of Hybrid Variable Regions" Molecular Immunology 32:407-416 (1995). Orlandi et al., "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction" Proc. Natl. Acad. Sci. USA 86:3833-3837 (May 1989). Orlandi et al., "Cloning of cDNA Corresponding to Heavy and Light Chain Immunoglobulin Variable Domains" Protein and Pharmaceutical Engineering pps. 90 (1989). Ostberg & Queen, "Human and humanized monoclonal antibodies: preclinical studies and clinical experience" Biochem. Soc. Transactions pps. 1038-1043 (1995). Padlan et al., "Model-Building Studies of Antigen-Binding Sites: The Hapten-Binding Site of MOPC-315" C.S. Harbor Symp. Quant. Biol. 41:627-637 (1977). Padlan et al., "Model-building Studies of Antigen-binding Sites: The Hapten-binding Site MOPC-315" Cold Springs Harbor Symposia On Quantitative Biology XLI:627-637 (1977). Padlan, E., "Anatomy of the Antibody Molecule" Molecular Immunology 31(3):169-217 (1994). Padlan, E., "Evaluation of the Structural Variation Among Light Chain Variable Domains" Molecular Immunology 16:287-296 (1979). Palm & Hilschmann, "Primary structure of a crystalline monoclonal immunoglobulin K-type L-chain, subgroup I (Bence-Jones preotin Rei); isolation & characterization of the tryptic peptides: . . . " Hoppes-Seyler's Z. Physiol. Chem. 356:167-191 (Feb. 1975). Palm & Hilschmann, "The primary structure of a crystalline, monoclonal immunoglobulin-L-chain of the x-type, subgroup I (Bence-Jones Protein Rei): a contribution to the elucidation of the three-dimensional structure of the immunoglobulins" Hoppe-Seyler's Z. Physiol. Chem. 354:1651-1654 (Dec. 1973). Panka et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies" Proc. Natl. Acad. Sci. USA 85:3080-3084 (May 1988). Pluckthun, Andreas, "Antibody engineering: advances from the use of Escherichia coli expression systems" Biotechnology 9:545-51 (1991). Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" Cancer Research 57(20):4593-4599 (Oct. 15, 1997). Presta et al., "Humanization of an Antibody Directed Against IgE" J. Immunol. 151(5):2623-2632 (Sep. 1, 1993). Preval & Fougereau, "Specific Interaction between V.sub.H and V.sub.L Regions of Human Monoclonal Immunoglobulins" J. Mol. Biol. 102:657-678 (1976). Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" Proc. Natl. Acad. Sci. USA 86(24):10029-10033 (Dec. 1989). Queen et al., "Construction of Humanized Antibodies and Testing in Primates" J. Cell. Biochem. Suppl. 15 (Part E) (20th Ann. Mtg. Keystone Symp. Denver, CO Mar. 10-16, 1991) pps. 137 (1991). Queen et al., "Humanised antibodies to the IL-2 receptor" Protein Eng. Antibody Mol. Prophyl. Ther. Appl. Man, Clark, M., Nottingham, UK:Academic Titles pps. 159-170 (1993). Rhodes & Birch, "Large-Scale Production of Proteins from Mammalian Cells" Bio/Technology 6:518, 521, 523 (May 1988). Riechmann & Winter, "Recombinant Antibodies" (U. of London Royal Postgraduate Medical School, Wolfson Institute, Abstract) (May 1987). Riechmann et al, "Expression of an Antibody Fv Fragment in Myeloma Cells" J. Mol. Biol. 203:825-828 (1988). Riechmann et al., "Reshaping Human Antibodies for Therapy" Nature 332:323-327 (Mar. 24, 1988). Riechmann, "Declaration" from EP Opposition to EP Patent No. 451,261 B1 (Oct. 22, 1996). Riechmann, "Humanizing of Recombinant Antibodies" (Intl. Symp. on Clin. Appl. of Monoclonal Antibodies, Guildford, England) pps. 33-34 (Sep. 1987). Roberts & Rees, "Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering" Nature 328:731-734 (Aug. 1987). Rodrigues et al., "Engineering a humanized bispecific F(ab').sub.2 fragment for improved binding to T cells" Int. J. Cancer (Suppl.) 7:45-50 (1992). Roitt et al. Immunology (Gower Medical Publishing Ltd., London, England) pps. 5.5 (1985). Rostapshov et al., "Effective method for obtaining long nucleotide chains on partially complementary templates" FEBS Letters 249(2):379-382 (Jun. 1989). Routledge et al., "A Humanized Monovalent CD3 Antibody which Can Activate Homologous Complement" European Journal of Immunology 21:2717-2725 (1991). Saul et al., "Preliminary refinement and structural analysis of the Fab fragment from human immunoglobulin new at 2.0 A resolution" Journal of Biological Chemistry 253(2):585-597 (Jan. 25, 1978). Schneider et al., "The Anti-Idiotypic Response by Cynomolgus Monkeys to Humanized Anti-Tac Is Primarily Directed to Complementarity-Determining Regions H1, H2, and L3" J. of Immunology 150:3086-3090 (Apr. 1993). Schroff, R. et al., "Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy" Cancer Research 45:879-885 (1985). Sedlacek et al., "Monoclonal Antibodies in Tumor Therapy", Karger pps. 119-126, 133-179 (1988). Segal et al., "The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site" Proc. Natl. Acad. Sci. USA 71(11):4298-4302 (Nov. 1974). Sha et al., "A Heavy-Chain Grafted Antibody that Recognizes the Tumor-Associated TAG72 Antigen" Cancer Biotherapy 9:341-349 (1994). Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" Journal of Experimental Medicine 175:217-225 (Jan. 1, 1992). Shearman et al., "Construction, Expression and Characterization of Humanized Antibodies Directed Against the Human .alpha./.beta. T Cell Receptor" J. Immunol. 147(12):4366-4373 (Dec. 15, 1991). Shepard and Lewis, "Resistance of tumor cells to tumor necrosis factor" J. Clin. Immunol. 8(5):333-395 (1988). Sheriff et al., "Three-dimensional structure of an antibody-antigen complex" Proc. Natl. Acad. Sci. USA 84(22):8075-8079 (Nov. 1987). Sherman et al., "Haloperidol binding to monoclonal antibodies" Journal of Biological Chemistry 263:4064-4074 (1988). Shields et al., "Inhibition of Allergic Reactions with Antibodies to IgE" International Archives of Allergy and Immunology 107(1-3):308-312 (May 1995). Silverton et al., "Three-dimensional structure of an intact human immunoglobulin" Proc. Natl. Acad. Sci. USA 74:5140-5144 (1977). Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" The Journal of Immunology 151(4):2296-2308 (Aug. 1993). Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" Science 235:177-182 (Jan. 9, 1987). Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" Science 244:707-712 (May 12, 1989). Smith-Gill et al., "A Three-dimensional Model of an Anti-lysozyme Antibody" Mol. Biol. 194:713-724 (1987). Snow and Amzel, "Calculating three-dimensional changes in protein structure due to amino-acid substitutions: the variable region of immunoglobulins" Protein: Structure, Function, and Genetics, Alan R. Liss, Inc. vol. 1:267-279 (1986). Songsivilai et al., "Bispecific antibody: a tool for diagnosis and treatment of disease" Clin. Exp. Immunol. 79:315-321 (1990). Sox et al., "Attachment of carbohydrate to the variable region of myeloma immunoglobulin light chains" Proc. Natl. Acad. Sci. USA 66:975-82 (Jul. 1970). Spiegelberg et al., "Localization of the carbohydrate within the variable region of light and heavy chains of human .gamma.G myeloma proteins" Biochemistry 9:4217-23 (Oct. 1970). Stanford, "A Predictive Method for Determining Possible Three-dimensional Foldings of Immunoglobulin Backbones Around Antibody Combining Sites" Theor. Biol. 88:421-439 (1981). Stickney et al., "Bifunctional Antibody: ZCE/CHA .sup.III Indium BLEDTA-IV Clinical Imaging in Colorectal Carcinoma" Antibody, Immuno Radiopharm 2:1-13 (1989). Takeda et al., "Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences" Nature 314(6010):452-454 (Apr. 4, 1985). Tao et al., "Studies of aglycosylated chimeric mouse-human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region" Journal of Immunology 143(8):2595-2601 (Oct. 15, 1989). Tempest et al., "Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus" Int. J. Biol. Macromol. 17:37-42 (1995). Tempest et al., "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo" Bio/Technology 9:266-271 (Mar. 1991). Tighe et al., "Delayed Allograft Rejection in Primates Treated with Anti-IL-2 Receptor Monoclonal antibody Campath-6" Transplantation 45(1):226-228 (Jan. 1988). Tramontano et al., "Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the V.sub.H domains of immunoglobulins" J. Mol. Biol. 215(1):175-182 (Sep. 5, 1990). Tramontano, "Structural Determinants of the Conformations of Medium-Sized Loops in Proteins" Proteins 6:382-394 (1989). Uchiyama et al., "A Monoclonal Antibody (ANTI-Tac) Reactive with Activated and Functionally Mature Human T Cells" Journal of Immunology 126:1393-1397 (1981). Verhoeyen & Riechmann, "Engineering of Antibodies" BioEssays 8(2):74-78 (Feb./Mar. 1988). Verhoeyen et al., "Grafting Hypervariable Regions in Antibodies" Protein Structure, Folding, and Design 2 (Proc. DuPont-UCLA Symp. Streamboat Springs, CO, Apr. 4-11, 1987), Dale L. Oxender, New York:Alan R. Liss, Inc. pps. 501-502 (1987). Verhoeyen et al., "Re-shaped human anti-PLAP antibodies" Monoclonal Antibodies Applications in clinical oncology, Epenetos, 1st edition, Chapman & Hall Medical pps. 37-43 (1991). Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" Science 239:1534-1536 (Mar. 25, 1988). Vincenti et al., "Interleukin-2-Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation" New Engl. J. Med. 338:161-165 (1998). Vitetta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents" Science 238:1098-1104 (1987). Waldmann et al., "Interleukin 2 Receptor (Tac Antigen) Expression in HTLV-1-associated Adult T-Cell Leukemia" Cancer Research 45:4559s-4562s (1985). Waldmann, T., "Monoclonal Antibodies in Diagnosis and Therapy" Science 252:1657-1662 (Jun. 1991). Waldmann, Thomas A., "The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes" Science 232:727-732 (1986). Wallick et al., "Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen" Journal of Experimental Medicine 168(3):1099-1109 (Sep. 1988). Ward et al., "Expression and Secretion of Repertoires of VH Domains in Escherichia coli: Isolation of Antigen Binding Activities" Progress in Immunology (7th Intl. Congress Immunol. Berlin, W. Germany), F. Melchers vol. VII:1144-1151 (1989). Ward, E.S. et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli" Nature 341:544-546 (1989). Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" J. of Immunology 157:4986-4995 (1996). Whittle et al., "Construction and Expression of A CDR-Grafted Anti-TNF Antibody" J. Cell Biochem. Suppl. 0 (Symp. on Protein and Pharm. Eng. Mol. and Cell. Biol. Park City, Utah)13 Part A:96 (1989). Winter & Neuberger, "Restructuring Enzymes and Antibodies" Investigation and Exploitation of Antibody Combining Sites, Eric Reid, Plenum Press pps. 139-140 (1985). Winter and Milstein, "Man-made antibodies" Nature 349(6307):293-299 (Jan. 24, 1991). Winter et al., "Protein Engineering by Site Directed Mutagenesis" Chemical Synthesis in Molecular Biology, H. Blocker et al., VCH pps. 189-197 (1987). Winter G., "Antibody Engineering" Phil. Trans. R. Soc. Lond. B 324:99-109 (1989). Woodle et al., "Humanized OKT3 Antibodies: Successful Transfer of Immune Modulating Properties and Idiotype Expression" J. of Immunology 148(9):2756-2763 (May 1992). Wu et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and Their Implications for Antibody Complementarity" Journal of Experimental Medicine 132:211-250 (1970). Yamamoto et al., "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor" Nature 319:230-234 (1986). Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" Nucl. Acids Res. 13(12):4431-4443 (Jun. 25, 1986). Carteron et al., "Treatment of Murine Lupus with F(ab')2 Fragments of Monoclonal Antibody to L3T4 (Suppression of Autoimmunity Does Not Depend on T Helper Cell Depletion)" J Immunol 142(5):1470-1475 (Mar. 1, 1999). Choy et al., "Effect of a humanised non-depleting anti-CD4 monoclonal antibody (mAb) on synovial fluid (SF) in rheumatoid arthritis (RA)" Arthritis and Rheumatism (abstract No. 130)abstract supplement (1997). Choy et al., "T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment II: clinical activity is related to pharmacodynamic effects" Immunology (abstract No. OGg378) 89(Suppl. 1) (1996). Choy et al., "T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment II: clinical activity is related to pharmacodynamic effects" Arthritis and Rheumatism (abstract No. 1301) abstract supplement (1996). Co et al., "Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody" Molecular Immunology 30(15):1361-1367 (Oct. 1993). Connolly et al., "T cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment III: immunological effects" Arthritis and Rheumatism (abstract No. 1302) abstract supplement (1996). Cunningham et al., "Receptor and Antibody Epitopes in Human Growth Hormone Identified by Homolog-Scanning Mutagenesis" Science 243:1330-1336 (1989). Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" Oncogene 2(4):387-394 (1988). Emery et al., "Humanised monoclonal antibodies for therapeutic applications" Exp. Opin. Invest. Drugs 3(3):241-251 (1994). Fan et al., "Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-.gamma.-interferon antibody" Journal of Molecular Recognition 12(1):19-32 (Jan.-Feb. 1999). Garrido et al., "Refocusing the Immune system to React with Human Tumors by Targeting Human LHuman Lymphocytes With Bispecific Antibodies" Devel. Biol. Standard 71:33-42 (1990). Gillies et al., "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities" Hum. Antibod. Hybridomas 1(1):47-54 (1990). Gorman et al., "Humanisation of monoclonal antibodies for therapy" Immunology 2:457-466 (1990). Heinrich et al., "Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions" Journal of Immunology 143(11):3589-3597 (Dec. 1, 1989). Kelley et al., "Antigen Binding Thermodynamics and Antiproliferative Effects of Chimeric and Humanized anti-p185.sup.HER2 Antibody Fab Fragments" Biochemistry 31:5434-5441 (1992). Kreitman et al., "Mik-.beta.(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the .beta.-chain of the IL-2 receptor" Journal of Immunology 149(8):2810-2815 (Oct. 15, 1992). Kuijpers et al., "Analysis of the Role of Leukocyte Function-Associated Antigen-1 in Activation of Human Influenza Virus-Specific T Cell Clones" J. of Immunology 144(9):3281-3287 (May 1, 1990). Leung et al., "Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments" Journal of Immunology 154:5919-5926 (1995). Mathieson et al., "Monoclonal-antibody therapy in systemic vasculitis" New England J. of Medicine 323(4):250-254 (Jul. 26, 1990). Osborne, Randall, "Full Approval of Breast Cancer Drug Expected by Year's End, FDA Panel OKs Genentech's Herceptin" Daily Ink pps. 1-2 (Sep. 4, 1998). Panayi et al., "T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment I: suppression of disease activity and acute phase response" Immunology (abstract OGg379) 89(suppl. 1) (1996). Panayi et al., "T cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment I: suppression of disease activity and acute phase response" Arthritis and Rheumatism (abstract No. 1300) abstract supplement (1996). Pegram et al., "Antibody dependent cell-mediated cytotoxicity in breast cancer patients in Phase III clinical trials of a humanized anti-HER2 antibody" Proceedings of the American Association for Cancer Research (Abstract No. 4044) 38:602 (Mar. 1997). Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity" Proc. Natl. Acad. Sci. USA 79:1979-1983 (1982). Sambrook et al., "Oligonucleotide-mediated Mutagenesis" Molecular Cloning A Laboratory Manual, Second edition, Cold Spring Harbor, NY:Cold Spring Harbor Laboratory Press pps. 15.51-15.56 (1989). Schanfield and Van Loghem, "Human immunoglobulin allotypes" Handbook of Experimental Immunology, Weir and Herzenberg, eds., Blackwell Scientific Publishers, Chapter 94, pps. 94.1-94.18 (1986). Tanimoto et al., "Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195" Leukemia 3(5):339-348 (May 1989). Tsudo et al., "Characterization of the interleukin 2 receptor .beta. chain using three distinct monoclonal antibodies" Proc. Natl. Acad. Sci. USA 86(6):1982-1986 (Mar. 1989). "ZENAPAX (Daclizumab) Sterile Concentrate for Injection" Physicians' Desk Reference (website version) (product information) pps. 1-8 (2001).

Citation

Cite This Patent

More From Subclass 388.1

More From Class 530